At Dholka, near Ahmedabad, our Biotechnology R&D and manufacturing facilities serve as the heart of our biologics work. We bring together comprehensive capabilities across research and development, GMP manufacturing, and analytics to serve a bigger purpose, advancing healthcare that truly makes a difference. Through these strengths, we strive to provide innovative, high-quality solutions to global healthcare challenges, with care, consistency, and scientific rigour at the core.
Backed by deep technical expertise, we continue to foster innovation while remaining dedicated to bringing accessible, affordable products to market, so that better treatment reaches more people, wherever they are.
Across molecular biology and manufacturing scale-up, our biotech capabilities are made to support every stage of biological product development with care, depth, and scientific accuracy.
Clone Development
Molecular assays
Clone stability studies
Series of SS fermenters and single-use bioreactors, process development, scale-up, and manufacturing
Insect cell baculovirus expression system for recombinant proteins
Virus culture, bacterial fermentation for natural and recombinant proteins
Mammalian cell culture system for recombinant proteins
Perfusion and continuous culture
Microbial culture
Batch and fed batch culture
Clarification
Chromatography techniques
Separation technologies
Technology transfer to manufacturing and scale-up
Solvent Extraction
Purification of natural and recombinant proteins
Development of a robust purification process
High-throughput DSP systems
Physico-chemical assay
Immunoanalysis
Biochemical assay
Potency assay
Animal model
Challenge assay
Cell-based assays
Glycan profiling
Our value proposition
| Product | Expression System |
|---|---|
| STPase | Thrombolytic agent is produced by fermentation |
| CADICRIT | Recombinant Erythropoietin Produced by Mammalian Cell Culture (CHO) |
| FILCAD | Recombinant Filgrastim produced by Bacterial Fermentation |
| Sepsivac | Produced from Bacterial Fermentation. Active immunotherapy against Gram-negative Sepsis |
| Mycidac-C | World’s first targeted active immunotherapy for non-small cell lung cancer |
| PEG-GCSF | Pegylation of in-house developed Filgrastim |
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
